Under President Trump, the Food and Drug Administration may no longer approve of seasonal COVID-19 vaccines that have been updated for the virus variants that are circulating that year, according to recent statements by the Trump administration officials.
Since the acute phase of the Pandemie, vaccine manufacturers have updated subtle COVID-19 recordings every year to accurately focus on the molecular signatures of the latest virus variants, which are constantly evolving to avoid our immune response. Until now, the FDA has treated these custom vaccines in the same way as seasonal flu shots, which have long been updated annually to match the currently circulating tribes of flu viruses.
The FDA does not take the seasonal flu shots into account brand new vaccines. Rather, they are only somewhat changed versions of the approved vaccines. As such, the regulator does not require that companies perform long -term, expensive vaccine tests to prove that every somewhat changed version is safe and effective. If they did, generating annual vaccines would be virtually impossible. Every year, from the end of February to the beginning of March, the FDA, the Centers for Disease Control and Prevention, and the World Health Organization Direct GriepPrik Makers about which tweaks they should make for shots for the coming flu season. That gives manufacturers just enough time to develop Tweaks and produce the production of massive doses on time before the start of the flu season.
Until now, COVID-19Gaccins have been treated in exactly the same way, except the fact that the vaccines that MRNA technology use do not need so much lead time for production. In recent years, the FDA decided around June formulations for annual COVIDSHOTS, with doses rolled out in the fall next to Flu Shots.
However, this process is now in question based on statements by Trump administration officials. The statements come in the midst of a delay in a decision to approve the COVID-19 vaccine made by Novavax, which uses a protein-based technology, not MRNA. The FDA was supposed to decide whether the vaccine would give full approval before 1 April. Until now, the vaccine has been used under the authorization of emergency use by the agency.
